Get access

Sublingual immunotherapy: the quest for innovative adjuvants


  • Conflict of interest disclosure: The Institute for Medical Immunology is sponsored by GSKBiologicals (Rixensart, Belgium) and Michel Goldman serves as consultant for GSKBiologicals and OM-Pharma (Meyrin, Switzerland).

  • This editorial discusses the findings of the paper in this issue by Lombardi et al. [7] pp. 1819-29

Michel Goldman, Institute for Medical Immunology, Université Libre de Bruxelles 8, Rue Adrienne Bolland, B-6041 Charleroi, Belgium. E-mail:

No abstract is available for this article.

Get access to the full text of this article